RHEACELL GmbH & Co. KG

RHEACELL is a biopharmaceutical company dedicated to developing drugs using a novel ABCB5-positive (ABCB5+) mesenchymal stem cell platform technology. RHEACELL has been granted national marketing authorization in Germany (§4b of the German Medicinal Products Act) for its cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds. RHEACELL is conducting several national and international multicenter clinical trials. RHEACELL holds orphan drug designation through the European Medicines Agency (EMA) and the United States Federal Drug Administration (FDA) for the treatment of epidermolysis bullosa (EB) and limbal stem cell deficiency (LSCD). RHEACELL has also received the "Fast Track Status" for treatment of LSCD from the FDA. The EMA's PDCO has also approved the pediatric investigation plan for RHEACELL's Epidermolysis Bullosa program.